Zealand initiates dosing of patients in Phase 2 with its stable glucagon analogue, ZP4207, for hypoglycemia in diabetes

· The Phase 2 trial is an important step in the dual product development of ZP4207: both as a rescue pen to treat severe hypoglycemia and as an essential component in an artificial pancreas device for better diabetes control

· Advancing ZP4207 into Phase 2 development is in line with Zealand's strategic focus on growing its pipeline of proprietary peptide medicines for accelerated value creation

· Trial completion and results are expected in H2 2016

COPENHAGEN, Denmark, Feb. 4, 2016 -- Zealand informs that the first patients have successfully been dosed in a Phase 2 trial with ZP4207 for the treatment and control of hypoglycemia associated with diabetes. ZP4207 is a novel stable glucagon analogue for liquid formulation, invented and fully owned by Zealand.

Attachments:

PR 01-16_0204 - Glucagon analogue ZP4207 advanced into Phase 2 - ENG_Final.pdf